Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients

被引:65
作者
Ollendorf, DA
Vera-Llonch, M
Oster, G
机构
[1] Policy Anal Inc, Brookline, MA 02445 USA
[2] PharMetr, Analyt Serv, Watertown, MA USA
[3] PharMetr, Consulting Serv, Watertown, MA USA
关键词
costs; economics; hospitals; surgery; toxicity; venous thrombosis;
D O I
10.1093/ajhp/59.18.1750
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The economic costs of clinical venous thromboembolism (VTE) in hospitalized patients after major orthopedic surgery were assessed. The discharge summaries and itemized bills from 200 U.S. acute care hospitals were examined. All patients who underwent total hip of knee replacement surgery or hip-fracture repair at these hospitals between January 1998 and June 1999 were identified and included in the study sample. Length of hospital stay, use of intensive care services and costs of inpatient care were compared between patients with and without secondary diagnoses of deep vein, thrombosis (DVT) without pulmonary embolism (PE) (DVT only) or PE with or without DVT. Mean length of hospital stay was more than twice as long for patients with VTE (11.5 and 12.4 days for DVT only and PE, respectively, versus 5.4 days for no VTE; rho < 0.0001 for both comparisons). Mean time in the intensive care unit was roughly 10-fold greater (1.7 days for DVT only and 2.7 days for PE versus 0.2 day for no VTE, rho < 0.0001). Mean total costs of inpatient care were almost twofold higher for patients with VTE ($17,114 for DVT only and $18,521 for PE versus $9,345 for no VTE, rho < 0.0001 for both comparisons). Findings were unchanged in multivariate analyses controlling for differences in baseline characteristics between patients with and without VTE. Patients who develop in-hospital clinical VTE following major orthopedic surgery have significantly longer stays in the hospital and approximately twofold higher costs of inpatient care.
引用
收藏
页码:1750 / 1754
页数:5
相关论文
共 25 条
[1]  
Agnelli G, 2000, ORTHOPEDICS, V23, pS643
[2]   WARFARIN PROPHYLAXIS TO PREVENT MORTALITY FROM PULMONARY-EMBOLISM AFTER TOTAL HIP-REPLACEMENT [J].
AMSTUTZ, HC ;
FRISCIA, DA ;
DOREY, F ;
CARNEY, BT .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1989, 71A (03) :321-326
[3]  
AMSTUTZ HC, 1992, SEMIN ARTHROPLASTY, V3, P99
[4]  
BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744
[5]   ENOXAPARIN - THE LOW-MOLECULAR-WEIGHT HEPARIN FOR PREVENTION OF POSTOPERATIVE THROMBOEMBOLIC COMPLICATIONS [J].
CARTER, CA ;
SKOUTAKIS, VA ;
SPIRO, TE ;
WEST, ME ;
TOOMS, RE ;
JOE, RH ;
KNUTSON, TJ .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (10) :1223-1230
[6]   PREVENTION OF VENOUS THROMBOEMBOLISM [J].
CLAGETT, GP ;
ANDERSON, FA ;
LEVINE, MN ;
SALZMAN, EW ;
WHEELER, HB .
CHEST, 1992, 102 (04) :S391-S407
[7]  
CLAGETT GP, 1995, CHEST S, V108, P312
[8]   USE OF ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN, AND UNFRACTIONATED HEPARIN FOR THE PREVENTION OF DEEP VENOUS THROMBOSIS AFTER ELECTIVE HIP-REPLACEMENT - A CLINICAL-TRIAL COMPARING EFFICACY AND SAFETY [J].
COLWELL, CW ;
SPIRO, TE ;
TROWBRIDGE, AA ;
MORRIS, BA ;
KWAAN, HC ;
BLAHA, JD ;
COMEROTA, AJ ;
SKOUTAKIS, VA .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1994, 76A (01) :3-14
[10]  
HAAKE DA, 1989, CLIN ORTHOP RELAT R, P212